FIGURE 1.

(A) The conventional pharmacovigilance approach involves applying a single detection method to SRS data to generate a single ranking of ADRs pairs. This ranking is subsequently submitted to a committee of medical experts. (B) The approach proposed in this paper entails the application of $Q$ distinct signal detection methods to EHC data, resulting in $Q$ rankings. These rankings are then amalgamated into a unified ranking using the Borda count method. The consolidated ranking is then presented to the committee. Furthermore, the option to conduct a verification study is provided to the committee as well. The $*$ indicates that, preferably, the EHC data are split into two sets: one for detection and one for the verification phase.